Biotech Values

[bladerunner1717]

re: CLDX


Celldex Announces Exercise of Over-Allotment Option


Companies:
Celldex Therapeutics, Inc.

Related Quotes
Symbol Price Change
CLDX 3.45 +0.10
Chart for Celldex Therapeutics, Inc
Press Release Source: Celldex Therapeutics, Inc. On Friday May 20, 2011, 9:20 am EDT

NEEDHAM, Mass.--(BUSINESS WIRE)-- Celldex Therapeutics, Inc. (Nasdaq:CLDX - News) today announced that the underwriters of its previously announced public offering of common stock have exercised in full their over-allotment option to purchase an additional 1,500,000 shares of common stock at the public offering price of $3.15 per share. Proceeds from the exercise of the option will be approximately $4.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The closing of the over-allotment option exercise is expected to occur on May 23, 2011, subject to customary closing conditions.

As previously announced, Celldex anticipates using the net proceeds from the offering, including the net proceeds from the exercise of the over-allotment option, to fund Celldex’s clinical trials of its product candidates and for working capital and other general corporate purposes.

Jefferies & Company, Inc. acted as the sole book-running manager of the offering. Wedbush Securities Inc., Brean Murray, Carret & Co. and Roth Capital Partners, LLC acted as co-managers of the offering.

A shelf registration statement relating to the shares was filed with the Securities and Exchange Commission and is effective. A prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement relating to these securities, may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, Inc., 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340, and at [e-mail].


Bladerunner